Organization: Health Canada
Year: 2023
Month: June
Request Number: A-2022-001256
Request Summary: Adverse Drug Reaction (ADR) for AGALSIDASE ALFA. Report number: E2B_05845814. ADRs for MEZAVANT. Report numbers: E2B_05870258, E2B_05864070. ADRs for LANSOPRAZOLE. Report numbers: E2B_05853179, E2B_05844531, E2B_05840815, 001021389, E2B_05875371, E2B_05874054.
Disposition: Disclosed in part
Number of pages: 333